Your daily pharma scoop: Nabriva‘s further potential, Allergan’s IP gimmick, Supernus Positive data
- Nabriva has further upside even from current highs.
- Allergan’s IP play using an Indian tribe’s sovereign immunity is analyzed.
- Supernus presents positive data in IA.
Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok Dutta, is writing a daily scoop of all sorts of news, catalysts, ratings, and other actionable details for its watch list stocks (and the rest of the healthcare universe). The watch list is available to Total Pharma Tracker subscribers. Some sections, like the catalyst data, abstract selections, AdComm coverages, Buy/Sell summaries etc are also available to subscribers only. This is an abridged version; for the entire Pharma Scoop, please subscribe to our Marketplace service.
Our daily analysis of a stock with a major event/upside: Nabriva’s further upside
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.